Last Price
1.62
Today's Change
-0.04 (2.40%)
Day's Change
1.62 - 1.67
Trading Volume
39,125
Market Cap
2 Million
Shares Outstanding
1 Million
Avg Volume
2,158,845
Avg Price (50 Days)
1.91
Avg Price (200 Days)
2.19
PE Ratio
-0.32
EPS
-5.14
Earnings Announcement
20-Mar-2025
Previous Close
1.66
Open
1.67
Day's Range
1.62 - 1.67
Year Range
1.22 - 7.2
Trading Volume
39,125
1 Day Change
-2.41%
5 Day Change
-10.50%
1 Month Change
-39.78%
3 Month Change
20.90%
6 Month Change
-14.74%
Ytd Change
-6.90%
1 Year Change
-64.16%
3 Year Change
-98.16%
5 Year Change
-99.10%
10 Year Change
-100.00%
Max Change
-100.00%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.